Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02957331 · ClinicalTrials.gov registry record · Phase 4
Beta Blockade in in Traumatic Brain Injury
A Phase 4 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT02957331 is a Phase 4 study that has completed, run by University of Tennessee. The registered enrollment target is 26 participants.
The verdict
NCT02957331, a Phase 4 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is test the effect of beta-adrenergic blockade on mortality in patients with traumatic brain injury with the hypothesis being that the addition of beta blockade to the treatment regime of this patient population will lower mortality and supress the catecholamine surge that accompanies traumatic brain injury as compared to those who do not receive beta blockade. Half the patients will be randomized to receive propranolol and half will be randomized to receive no beta blocker.
Interventions
- DRUG Propranolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02957331
The ClinicalTrials.gov registry entry for NCT02957331 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Propranolol is the first listed.
NCT02957331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02957331 about?
NCT02957331 is a clinical study titled "Beta Blockade in in Traumatic Brain Injury". The purpose of this study is test the effect of beta-adrenergic blockade on mortality in patients with traumatic brain injury with the hypothesis being that the addition of beta blockade to the treatment regime of this patient population will lower mortality and supress the catecholamine surge that ...
What is the current status of trial NCT02957331?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2016-01. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02957331?
The interventions under investigation include: Propranolol (DRUG).
Who is sponsoring clinical trial NCT02957331?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.